TECHULON INC has a total of 25 patent applications. Its first patent ever was published in 2014. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and macromolecular chemistry and polymers are PALESE PETER, MEDIGEN INC and IMMUNICUM AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | United States | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Canada | 3 | |
#5 | Singapore | 3 | |
#6 | Israel | 2 | |
#7 | Republic of Korea | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Macromolecular chemistry and polymers | |
#4 | Computer technology | |
#5 | Environmental technology | |
#6 | Basic materials chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Malone Brett | 18 |
#2 | Bryson Joshua | 18 |
#3 | Miriyala Bruhaspathy | 5 |
#4 | Mohapatra Nrusingh Prasad | 4 |
#5 | Guennet Denis K | 4 |
#6 | Guenette Denis | 1 |
#7 | Mohapatra Nrusingh P | 1 |
#8 | Lee Eunkyung | 1 |
Publication | Filing date | Title |
---|---|---|
WO2019232059A1 | Antisense oligonucleotides for the treatment of p. aeruginsoa, a. baumannii and k. pneumoniae infections | |
EP3704253A1 | Peptide nucleic acid molecules for treatment of gram positive bacterial infection | |
WO2016200926A1 | Peptide nucleic acid molecules for treatment of gram positive bacterial infection | |
EP2969011A2 | Rapidly adaptable nano therapeutics for treatment of infectious disease | |
SG11201507142QA | Antisense molecules for treatment of staphylococcus aureus infection | |
EP2970976A2 | Antisense molecules for treatment of staphylococcus aureus infection |